Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Olaparib (Lynparza) for metastatic breast cancer with germline BRCA mutation – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Breast cancer is the most common cancer in the UK. BRCA genes make proteins that help repair damaged DNA. Women with a BRCA gene mutation have a much higher risk of breast and other cancers. Most women who get breast cancer are over 50 years of age. However, people that have a breast cancer with BRCA gene mutation often get it at a younger age.
Olaparib is a new treatment for breast cancer with germline BRCA mutation that can be taken by mouth as a capsule. Some studies have suggested olaparib may be helpful for people whose first chemotherapy treatment has failed and more studies are now aiming to show how well it works and that it is safe to use. Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibitors; Humans; Mutation; Phthalazines; Piperazines Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000520 Date abstract record published 15/03/2016 |